Scientific Publications & Presentations

Scientific Publications, Verva Pharmaceuticals - Biotech Australia

Verva’s scientists will be presentating and publishing the results of Verva’s Research and Development programs.  Selected publications to date are included below:

VVP808

Simpson RW, Nicholson GC, Proietto J, Sarah A, Sanders KM, Phillips G, Chambers J, MacGinley R, Orford N, Walder K, Krippner G, Skoff K, Wacher VJ. (2014). Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study.  Diabetes Care. 37(11): 3121-3 (PMID: 25125506).

Konstantopoulos N, Molero JC, McGee SL, Spolding B, Connor T, de Vries M, Wanyonyi S, Fahey R, Morrison S, Swinton C, Jones S, Cooper A, Garcia-Guerra L, Foletta VC, Krippner G, Andrikopoulos S, Walder KR. (2012).  Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo.  Diabetes 61(8): 2 146-54 (PMID:  2258659)

Walder K, Konstantopoulos N, Windmill K, Molero-Navajas J, Krippner G, Collier G.  [Abstract].  Mechanism of action of VVP808: A novel insulin sensitising agent.  European Association for the Study of Diabetes Annual Meeting. Lisbon, Portugal. 12-16 September 2011.

GES Technology

Konstantopoulos N, Foletta VC, Segal DH, Shields KA, Sanigorski A, Windmill K, Swinton C, Connor T, Wanyonyi S, Dyer TD, Fahey RP, Watt RA, Curran JE, Molero JC, Krippner G, Collier GR, James DE, Blangero J, Jowett JB, Walder KR.  (2011).  A gene expression signature for insulin resistance.  Physiol Genomics 43(3): 110-20.  (PMID 21081660)